{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:19:14Z","timestamp":1793949554140,"version":"4.8.0"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK114211"],"award-info":[{"award-number":["DK114211"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK103804"],"award-info":[{"award-number":["DK103804"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.neuropharm.2017.12.016","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T09:37:22Z","timestamp":1512812242000},"page":"287-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"PB","title":["Amylin in Alzheimer's disease: Pathological peptide or potential treatment?"],"prefix":"10.1016","volume":"136","author":[{"given":"Elizabeth G.","family":"Mietlicki-Baase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.12.016_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","article-title":"Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition","volume":"35","author":"Adler","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Alzheimer's","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib3","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1002\/anie.200904902","article-title":"Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association","volume":"49","author":"Andreetto","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib4","first-page":"R1654","article-title":"Chronic infusion of islet amyloid polypeptide causes anorexia in rats","volume":"271","author":"Arnelo","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1476-5381.2011.01717.x","article-title":"Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes","volume":"166","author":"Bailey","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib6","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/npp.2014.153","article-title":"Amylin receptor signaling in the nucleus accumbens negatively modulates mu-opioid-driven feeding","volume":"39","author":"Baisley","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0196-9781(98)00018-7","article-title":"Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin","volume":"19","author":"Banks","year":"1998","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib8","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/0024-3205(95)02197-Q","article-title":"Permeability of the blood-brain barrier to amylin","volume":"57","author":"Banks","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib9","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1039\/C5CP03338A","article-title":"Amylin-Abeta oligomers at atomic resolution using molecular dynamics simulations: a link between Type 2 diabetes and Alzheimer's disease","volume":"18","author":"Baram","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4239\/wjd.v5.i6.889","article-title":"Type 2 diabetes mellitus and Alzheimer's disease","volume":"5","author":"Barbagallo","year":"2014","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.brainres.2003.10.040","article-title":"Peripheral amylin activates circumventricular organs expressing calcitonin receptor a\/b subtypes and receptor-activity modifying proteins in the rat","volume":"997","author":"Barth","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015746","article-title":"Signs and symptoms preceding the diagnosis of Alzheimer's disease: a systematic scoping review of literature from 1937 to 2016","volume":"7","author":"Bature","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0026-895X(25)13212-4","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib14","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1021\/cn400141x","article-title":"In silico cross seeding of Abeta and amylin fibril-like oligomers","volume":"4","author":"Berhanu","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0014-5793(89)81467-X","article-title":"Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species","volume":"251","author":"Betsholtz","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/nbdi.1995.0019","article-title":"Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing","volume":"2","author":"Biere","year":"1995","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/j.1582-4934.2011.01318.x","article-title":"Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis","volume":"15","author":"Bosco","year":"2011","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development","volume":"173","author":"Bower","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00198-003-1538-5","article-title":"Amylin fasting plasma levels are decreased in patients with osteoporosis","volume":"15","author":"Bronsky","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib20","first-page":"24","article-title":"What's new in clinical pharmacology and therapeutics","volume":"105","author":"Chawla","year":"2006","journal-title":"Wis. Med. J."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF01925572","article-title":"Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat","volume":"52","author":"Clementi","year":"1996","journal-title":"Experientia"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.2000.tb06195.x","article-title":"Microglial contribution to oxidative stress in Alzheimer's disease","volume":"899","author":"Colton","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib23","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1111\/j.1742-4658.2009.07061.x","article-title":"Insulin is a kinetic but not a thermodynamic inhibitor of amylin aggregation","volume":"276","author":"Cui","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer's disease: the path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/NEN.0b013e318217a118","article-title":"Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein\/tau transgenic mice","volume":"70","author":"DaRocha-Souto","year":"2011","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.31887\/DCNS.2009.11.2\/pdavies","article-title":"Mechanism-based treatments for Alzheimer's disease","volume":"11","author":"Davies","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib28","first-page":"E785","article-title":"Human aging is associated with parallel reductions in insulin and amylin release","volume":"275","author":"Dechenes","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/14789450.2013.841549","article-title":"Amylin: what might be its role in Alzheimer's disease and how could this affect therapy?","volume":"10","author":"Despa","year":"2013","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/brain\/awq065","article-title":"The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia","volume":"133","author":"Mc Donald","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib31","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1073\/pnas.94.9.4772","article-title":"Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity","volume":"94","author":"Dore","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib32","doi-asserted-by":"crossref","first-page":"R355","DOI":"10.1152\/ajpregu.00462.2015","article-title":"Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity","volume":"310","author":"Dunn-Meynell","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1385\/MN:26:2-3:299","article-title":"Intracellular A-beta amyloid, a sign for worse things to come?","volume":"26","author":"Echeverria","year":"2002","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0047-6374(95)01664-3","article-title":"Age-related changes in amylin secretion","volume":"86","author":"Edwards","year":"1996","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cell.2012.02.022","article-title":"The amyloid state of proteins in human diseases","volume":"148","author":"Eisenberg","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2174\/1567205011666141107124538","article-title":"Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer's disease","volume":"11","author":"Fawver","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib37","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/0006-291X(90)90636-2","article-title":"Islet amyloid polypeptide (IAPP;amylin) influences the endocrine but not the exocrine rat pancreas","volume":"167","author":"Fehmann","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib38","doi-asserted-by":"crossref","first-page":"18820","DOI":"10.1074\/jbc.M111.331181","article-title":"Amyloid beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways","volume":"287","author":"Fu","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.expneurol.2009.09.001","article-title":"Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model","volume":"223","author":"Gaspar","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1210\/en.2013-1658","article-title":"Activity of pramlintide, rat and human amylin but not Abeta1-42 at human amylin receptors","volume":"155","author":"Gingell","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000026432","article-title":"Human amylin stimulates inflammatory cytokine secretion from human glioma cells","volume":"7","author":"Gitter","year":"2000","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1006\/jsbi.2000.4268","article-title":"Amyloid fibril formation from full-length and fragments of amylin","volume":"130","author":"Goldsbury","year":"2000","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnagi.2013.00038","article-title":"Lessons from two prevalent amyloidoses-what amylin and Abeta have in common","volume":"5","author":"Gotz","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/alzrt272","article-title":"Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics","volume":"6","author":"Goure","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bcp.2013.12.023","article-title":"Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins","volume":"88","author":"Guerrero-Munoz","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib46","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archinte.163.13.1524","article-title":"An 18-year follow-up of overweight and risk of Alzheimer disease","volume":"163","author":"Gustafson","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharmthera.2005.06.015","article-title":"GPCR modulation by RAMPs","volume":"109","author":"Hay","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib49","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib50","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0306-4522(95)00322-A","article-title":"In\u00a0vitro autoradiographic localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain","volume":"69","author":"Hilton","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib51","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1073\/pnas.96.6.3228","article-title":"Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models","volume":"96","author":"Hsia","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","article-title":"Amylin deposition in the brain: a second amyloid in Alzheimer disease?","volume":"74","author":"Jackson","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10495-011-0656-3","article-title":"beta-Amyloid protein (Abeta) and human amylin regulation of apoptotic genes occurs through the amylin receptor","volume":"17","author":"Jhamandas","year":"2012","journal-title":"Apoptosis"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajpath.2010.11.022","article-title":"Actions of beta-amyloid protein on human neurons are expressed through the amylin receptor","volume":"178","author":"Jhamandas","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib55","first-page":"245","article-title":"Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells","volume":"135","author":"Johnson","year":"1989","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib56","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0006-291X(90)90359-U","article-title":"Canine IAPP cDNA sequence provides important clues regarding diabetogenesis and amyloidogenesis in type 2 diabetes","volume":"169","author":"Jordan","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-015-0693-3","article-title":"GLP-1 and amylin in the treatment of obesity","volume":"16","author":"Jorsal","year":"2016","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib58","doi-asserted-by":"crossref","first-page":"14077","DOI":"10.1074\/jbc.275.19.14077","article-title":"Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line","volume":"275","author":"Kawahara","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib59","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","article-title":"Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease","volume":"21","author":"Kawarabayashi","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib60","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12035-016-9684-x","article-title":"Pramlintide antagonizes beta amyloid (abeta)- and human amylin-induced depression of hippocampal long-term potentiation","volume":"54","author":"Kimura","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib61","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/archneur.62.10.1556","article-title":"Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease","volume":"62","author":"Kivipelto","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib62","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00400683","article-title":"Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM","volume":"39","author":"Kolterman","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib63","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1111\/j.1742-4658.2006.05367.x","article-title":"The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells","volume":"273","author":"Konarkowska","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib64","doi-asserted-by":"crossref","first-page":"9989","DOI":"10.1073\/pnas.96.18.9989","article-title":"Amyloid diseases: abnormal protein aggregation in neurodegeneration","volume":"96","author":"Koo","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib65","first-page":"84","article-title":"An update of animal models of Alzheimer disease with a reevaluation of plaque depositions","volume":"22","author":"Lee","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.neuroscience.2007.10.054","article-title":"Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function","volume":"151","author":"Lesne","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib67","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JAD-160114","article-title":"An update on type 2 diabetes mellitus as a Risk factor for dementia","volume":"53","author":"Li","year":"2016","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib68","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cmet.2015.10.012","article-title":"Hypothalamic amylin acts in concert with leptin to regulate food intake","volume":"22","author":"Li","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-150428","article-title":"Age and its association with low insulin and high amyloid-beta peptides in blood","volume":"49","author":"Li","year":"2016","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib70","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2147\/NDT.S111298","article-title":"Type 2 diabetes mellitus might be a risk factor for mild cognitive impairment progressing to Alzheimer's disease","volume":"12","author":"Li","year":"2016","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib71","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/ejn.13163","article-title":"Amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons","volume":"43","author":"Liberini","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.1996.tb34406.x","article-title":"Amyloid fibril toxicity in Alzheimer's disease and diabetes","volume":"777","author":"Lorenzo","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib73","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/368756a0","article-title":"Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus","volume":"368","author":"Lorenzo","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib74","doi-asserted-by":"crossref","first-page":"R1475","DOI":"10.1152\/ajpregu.00703.2009","article-title":"The role of amylin in the control of energy homeostasis","volume":"298","author":"Lutz","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000264394","article-title":"Roles of amylin in satiation, adiposity and brain development","volume":"63","author":"Lutz","year":"2010","journal-title":"Forum Nutr."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnins.2015.00216","article-title":"Amylin at the interface between metabolic and neurodegenerative disorders","volume":"9","author":"Lutz","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib77","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0031-9384(94)90076-0","article-title":"Reduction of food intake in rats by intraperitoneal injection of low doses of amylin","volume":"55","author":"Lutz","year":"1994","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib78","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0196-9781(94)00203-I","article-title":"Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin","volume":"16","author":"Lutz","year":"1995","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib79","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0031-9384(95)02067-5","article-title":"Amylin decreases meal size in rats","volume":"58","author":"Lutz","year":"1995","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib80","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.ijo.0801664","article-title":"The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema\/nucleus of the solitary tract (AP\/NTS) lesioned rats","volume":"25","author":"Lutz","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib81","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/14789450.2015.1104251","article-title":"Hyperamylinemia as a risk factor for accelerated cognitive decline in diabetes","volume":"12","author":"Ly","year":"2015","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib82","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ana.24992","article-title":"Brain microvascular injury and white matter disease provoked by diabetes-associated hyperamylinemia","volume":"82","author":"Ly","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib83","doi-asserted-by":"crossref","first-page":"37102","DOI":"10.1074\/jbc.M110.133488","article-title":"Polymorphic C-terminal beta-sheet interactions determine the formation of fibril or amyloid beta-derived diffusible ligand-like globulomer for the Alzheimer Abeta42 dodecamer","volume":"285","author":"Ma","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib84","doi-asserted-by":"crossref","first-page":"R1855","DOI":"10.1152\/ajpregu.00297.2007","article-title":"Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight","volume":"293","author":"Mack","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ijo.2009.238","article-title":"Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight","volume":"34","author":"Mack","year":"2010","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib86","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2146\/ajhp050341","article-title":"Pramlintide acetate","volume":"62","author":"McQueen","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib87","doi-asserted-by":"crossref","first-page":"E1317","DOI":"10.1152\/ajpendo.00082.2006","article-title":"Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP","volume":"291","author":"Meier","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib88","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1523\/JNEUROSCI.2984-08.2009","article-title":"Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice","volume":"29","author":"Meilandt","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib89","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.physbeh.2016.02.034","article-title":"Amylin-mediated control of glycemia, energy balance, and cognition","volume":"162","author":"Mietlicki-Baase","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.physbeh.2014.01.013","article-title":"Amylin activates distributed CNS nuclei to control energy balance","volume":"136","author":"Mietlicki-Baase","year":"2014","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib91","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/npp.2013.66","article-title":"Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake","volume":"38","author":"Mietlicki-Baase","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib92","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3233\/JAD-160800","article-title":"Amylin enhances amyloid-beta peptide brain to blood efflux across the blood-brain barrier","volume":"56","author":"Mohamed","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.physbeh.2004.01.006","article-title":"Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats","volume":"81","author":"Mollet","year":"2004","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib94","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1210\/en.2007-1735","article-title":"Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors","volume":"149","author":"Morfis","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib95","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cocis.2011.06.016","article-title":"Assembly of Alzheimer's A\u03b2 peptide into nanostructured amyloid fibrils","volume":"16","author":"Morgado","year":"2011","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2015.11.005","article-title":"Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin","volume":"39","author":"Morris","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib97","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neubiorev.2015.08.021","article-title":"Obesity and sex interact in the regulation of Alzheimer's disease","volume":"67","author":"Moser","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib98","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yexcr.2014.12.014","article-title":"Amyloid-beta precursor protein: multiple fragments, numerous transport routes and mechanisms","volume":"334","author":"Muresan","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fendo.2014.00070","article-title":"Cytokines and hormones that contribute to the positive association between fat and bone","volume":"5","author":"Naot","year":"2014","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib101","doi-asserted-by":"crossref","first-page":"10311","DOI":"10.1074\/jbc.M608207200","article-title":"Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct","volume":"282","author":"Necula","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0168-8227(92)90065-Y","article-title":"Molecular biology of islet amyloid polypeptide","volume":"15","author":"Nishi","year":"1992","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib103","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI114528","article-title":"Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment","volume":"85","author":"Ogawa","year":"1990","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00400272","article-title":"Sequences of islet amyloid polypeptide precursors of an Old World monkey, the pig-tailed macaque (Macaca nemestrina), and the dog (Canis familiaris)","volume":"34","author":"Ohagi","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib105","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.0953-816x.2001.01688.x","article-title":"Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat","volume":"14","author":"Oliver","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib106","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.peptides.2007.06.011","article-title":"Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat","volume":"28","author":"Olsson","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib107","article-title":"Alzheimer's disease as oligomeropathy","author":"Ono","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib108","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bbadis.2014.01.002","article-title":"Exogenous amyloidogenic proteins function as seeds in amyloid beta-protein aggregation","volume":"1842","author":"Ono","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib109","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1084\/jem.5.4.397","article-title":"On the relation of chronic interstitial pancreatitis to the Islands of Langerhans and to diabetes melutus","volume":"5","author":"Opie","year":"1901","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jchemneu.2004.03.005","article-title":"In\u00a0vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain","volume":"27","author":"Paxinos","year":"2004","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib111","first-page":"E156","article-title":"Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity","volume":"267","author":"Pieber","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib112","doi-asserted-by":"crossref","first-page":"826706","DOI":"10.1155\/2013\/826706","article-title":"Amylin uncovered: a review on the polypeptide responsible for type II diabetes","volume":"2013","author":"Pillay","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib113","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.bbadis.2013.04.017","article-title":"Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis","volume":"1832","author":"Platt","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib114","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/pr.54.2.233","article-title":"International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors","volume":"54","author":"Poyner","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","article-title":"Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes","volume":"2","author":"Pullman","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib116","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2005.01.004","article-title":"Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis","volume":"27","author":"Qiu","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib117","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fnagi.2014.00186","article-title":"Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?","volume":"6","author":"Qiu","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib118","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-140210","article-title":"Positive association between plasma amylin and cognition in a homebound elderly population","volume":"42","author":"Qiu","year":"2014","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib119","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib120","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/oby.2007.239","article-title":"Amylin and its relation to insulin and lipids in obese children before and after weight loss","volume":"15","author":"Reinehr","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib121","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.biopsych.2016.12.028","article-title":"Amylin acts in the lateral dorsal tegmental nucleus to regulate energy balance through gamma-aminobutyric acid signaling","volume":"82","author":"Reiner","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib122","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00702-017-1763-2","article-title":"The diabetic brain and cognition","volume":"124","author":"Riederer","year":"2017","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib123","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/brain\/awx057","article-title":"Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET","volume":"140","author":"Roberts","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib124","doi-asserted-by":"crossref","first-page":"10836","DOI":"10.1073\/pnas.90.22.10836","article-title":"beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease","volume":"90","author":"Roher","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2017.08.007","article-title":"APP\/Abeta structural diversity and Alzheimer's disease pathogenesis","volume":"110","author":"Roher","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib126","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbadis.2008.12.003","article-title":"(Pre)diabetes, brain aging, and cognition","volume":"1792","author":"Roriz-Filho","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib127","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib128","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrendo.2013.47","article-title":"Emerging combinatorial hormone therapies for the treatment of obesity and T2DM","volume":"9","author":"Sadry","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/rej.2008.0689","article-title":"Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease","volume":"11","author":"Solomon","year":"2008","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.trci.2016.11.005","article-title":"Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease","volume":"3","author":"Soudy","year":"2017","journal-title":"Alzheimer's Dementia: Translational Research & Clinical Interventions"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib131","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4239\/wjd.v6.i5.744","article-title":"Emerging links between type 2 diabetes and Alzheimer's disease","volume":"6","author":"Sridhar","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/pin.12520","article-title":"Plaque formation and the intraneuronal accumulation of beta-amyloid in Alzheimer's disease","volume":"67","author":"Takahashi","year":"2017","journal-title":"Pathol. Int."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib133","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1096\/fj.13-229666","article-title":"Brain interstitial oligomeric amyloid beta increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease","volume":"27","author":"Takeda","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib134","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib135","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib136","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/psc.2513","article-title":"Effect of agitation on the peptide fibrillization: alzheimer's amyloid-beta peptide 1-42 but not amylin and insulin fibrils can grow under quiescent conditions","volume":"19","author":"Tiiman","year":"2013","journal-title":"J.\u00a0Pept. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib137","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-3565(24)39040-8","article-title":"Amylin receptor phenotypes derived from human calcitonin receptor\/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment","volume":"294","author":"Tilakaratne","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib138","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/1060028015573010","article-title":"Pharmacologic treatment of type 2 diabetes: injectable medications","volume":"49","author":"Tran","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib139","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1471-4159.1998.71020506.x","article-title":"Human amylin induces \"apoptotic\" pattern of gene expression concomitant with cortical neuronal apoptosis","volume":"71","author":"Tucker","year":"1998","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0169-328X(01)00179-6","article-title":"Expression of receptor-activity modifying protein (RAMP) mRNAs in the mouse brain","volume":"93","author":"Ueda","year":"2001","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib141","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/CIA.S48926","article-title":"Type 2 diabetes as a risk factor for cognitive impairment: current insights","volume":"9","author":"Umegaki","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib142","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-pharmtox-010716-104735","article-title":"New targets for drug treatment of obesity","volume":"57","author":"Valsamakis","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib143","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib144","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JAD-160677","article-title":"Amylin treatment reduces neuroinflammation and ameliorates abnormal patterns of gene expression in the cerebral cortex of an Alzheimer's disease mouse model","volume":"56","author":"Wang","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fgene.2014.00088","article-title":"Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models","volume":"5","author":"Webster","year":"2014","journal-title":"Front. Genet."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib146","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00432160","article-title":"Amyloid of human islets of Langerhans. II. Electron microscopic analysis of isolated amyloid","volume":"373","author":"Westermark","year":"1977","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib147","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","article-title":"Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib148","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-5793(95)01512-4","article-title":"Effects of beta cell granule components on human islet amyloid polypeptide fibril formation","volume":"379","author":"Westermark","year":"1996","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.neuropharm.2017.12.016_bib149","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1096\/fj.201700431R","article-title":"Amyloid-beta and islet amyloid pathologies link Alzheimer disease and type 2 diabetes in a transgenic model","volume":"31","author":"Wijesekara","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1615\/CritRevNeurobiol.v11.i2-3.40","article-title":"Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily","volume":"11","author":"Wimalawansa","year":"1997","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib151","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1073\/pnas.82.24.8729","article-title":"Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related","volume":"82","author":"Wong","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib152","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1440-1681.1998.tb02272.x","article-title":"Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension","volume":"25","author":"Wookey","year":"1998","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib153","first-page":"1642","article-title":"Amylin in the periphery II: an updated mini-review","volume":"6","author":"Wookey","year":"2006","journal-title":"Sci. Tech. Rep."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib154","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jnen\/59.8.723","article-title":"Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects","volume":"59","author":"Yamaguchi","year":"2000","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib155","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2174\/13816128113199990064","article-title":"Molecular characterization of the hetero-assembly of beta-amyloid peptide with islet amyloid polypeptide","volume":"20","author":"Yan","year":"2014","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib156","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1054-3589(05)52014-3","article-title":"Cardiovascular effects","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib157","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1054-3589(05)52016-7","article-title":"Effects on bone","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib158","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1054-3589(05)52015-5","article-title":"Renal effects","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib159","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2011.581663","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction","volume":"12","author":"Younk","year":"2011","journal-title":"Expet Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.neuropharm.2017.12.016_bib160","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1515\/revneuro-2017-0016","article-title":"Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review","volume":"28","author":"Yuan","year":"2017","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib161","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/alzrt211","article-title":"The role of APP and BACE1 trafficking in APP processing and amyloid-beta generation","volume":"5","author":"Zhang","year":"2013","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib162","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pneurobio.2017.03.001","article-title":"Islet amyloid polypeptide: another key molecule in Alzheimer's pathogenesis?","volume":"153","author":"Zhang","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib163","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diabres.2016.10.024","article-title":"An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer's disease","volume":"124","author":"Zhang","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib164","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2016.07.008","article-title":"Multiple target of hAmylin on rat primary hippocampal neurons","volume":"113","author":"Zhang","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.016_bib166","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trci.2016.12.002","article-title":"An amylin analog used as a challenge test for Alzheimer's disease","volume":"3","author":"Zhu","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.neuropharm.2017.12.016_bib167","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neuropharm.2017.03.030","article-title":"Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease","volume":"119","author":"Zhu","year":"2017","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817306056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817306056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T13:04:01Z","timestamp":1751115841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817306056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":167,"alternative-id":["S0028390817306056"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.016","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amylin in Alzheimer's disease: Pathological peptide or potential treatment?","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}